Rare Diseases International. Operational description of rare diseases. Rare Diseases International https://www.rarediseasesinternational.org/fr/definition-operationnelle-des-maladies-rares/ (2023).

Haendel, M. et al. How many rare diseases are there? Nat. Rev. Drug. Discov. 19, 77–78 (2020).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Boycott, K. M. & Ardigó, D. Addressing challenges in the diagnosis and treatment of rare genetic diseases. Nat. Rev. Drug. Discov. 17, 151–152 (2018).

Article  PubMed  CAS  Google Scholar 

Smith, C. I. E., Bergman, P. & Hagey, D. W. Estimating the number of diseases—the concept of rare, ultra-rare, and hyper-rare. iScience 25, 104698 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Dawkins, H. J. S. et al. Progress in rare diseases research 2010–2016: an IRDiRC Perspective. Clin. Transl. Sci. 11, 11–20 (2018).

Article  PubMed  Google Scholar 

Fonseca, D. A., Amaral, I., Pinto, A. C. & Cotrim, M. D. Orphan drugs: major development challenges at the clinical stage. Drug. Discov. Today 24, 867–872 (2019).

Article  PubMed  Google Scholar 

US Food and Drug Administration. Rare diseases: common issues in drug development guidance for industry. FDA https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-diseases-common-issues-drug-development-guidance-industry (2020).

Nguengang Wakap, S. et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur. J. Hum. Genet. 28, 165–173 (2020).

Article  PubMed  Google Scholar 

Straub, V. et al. Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. Lancet Neurol. 15, 882–890 (2016).

Article  PubMed  Google Scholar 

Denton, N. et al. Sharing is caring: a call for a new era of rare disease research and development. Orphanet J. Rare Dis. 17, 389 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Boycott, K. M., Lau, L. P., Cutillo, C. M. & Austin, C. P. International collaborative actions and transparency to understand, diagnose, and develop therapies for rare diseases. EMBO Mol. Med. 11, e10486 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Julkowska, D. et al. The importance of international collaboration for rare diseases research: a European perspective. Gene Ther. 24, 562–571 (2017).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Austin, C. P. et al. Future of rare diseases research 2017–2027: an IRDiRC Perspective. Clin. Transl. Sci. 11, 21–27 (2018).

Article  PubMed  Google Scholar 

Dos Santos Vieira, B. et al. Towards FAIRification of sensitive and fragmented rare disease patient data: challenges and solutions in European reference network registries. Orphanet J. Rare Dis. 17, 436 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Sun, W., Zheng, W. & Simeonov, A. Drug discovery and development for rare genetic disorders. Am. J. Med. Genet. A 173, 2307–2322 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Hechtelt Jonker, A. et al. Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook. Nat. Rev. Drug. Discov. 19, 495–496 (2020).

Article  PubMed  CAS  Google Scholar 

Tambuyzer, E. et al. Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nat. Rev. Drug. Discov. 19, 93–111 (2020).

Article  PubMed  CAS  Google Scholar 

Kim, J. et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N. Engl. J. Med. 381, 1644–1652 (2019).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bateman-House, A. & Kearns, L. Individualized therapeutics development for rare diseases: the current ethical landscape and policy responses. Nucleic Acid. Ther. 32, 111–117 (2022).

Article  PubMed  CAS  Google Scholar 

Individualized ASO therapy for rare diseases. Commun. Med. 3, 27 (2023).

Griggs, R. C. et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol. Genet. Metab. 96, 20–26 (2009).

Article  PubMed  CAS  Google Scholar 

Augustine, E. F., Adams, H. R. & Mink, J. W. Clinical trials in rare disease: challenges and opportunities. J. Child. Neurol. 28, 1142–1150 (2013).

Article  PubMed  PubMed Central  Google Scholar 

Rinaldi, C. & Wood, M. J. A. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat. Rev. Neurol. 14, 9–21 (2018).

Article  PubMed  CAS  Google Scholar 

Lauffer, M. C., van Roon-Mom, W. & Aartsma-Rus, A. Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders. Commun. Med. 4, 1–11 (2024).

Article  Google Scholar 

Gene therapy for rare diseases. Nat. Genet. 22, 313–314 (1999).

Bashor, C. J., Hilton, I. B., Bandukwala, H., Smith, D. M. & Veiseh, O. Engineering the next generation of cell-based therapeutics. Nat. Rev. Drug. Discov. 21, 655–675 (2022).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lin, M. J. et al. Cancer vaccines: the next immunotherapy frontier. Nat. Cancer 3, 911–926 (2022).

Article  PubMed  CAS  Google Scholar 

Ebrahimi, S. B. & Samanta, D. Engineering protein-based therapeutics through structural and chemical design. Nat. Commun. 14, 2411 (2023).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li, T. et al. CRISPR/Cas9 therapeutics: progress and prospects. Sig Transduct. Target. Ther. 8, 1–23 (2023).

Google Scholar 

Corey, D. R. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Nat. Neurosci. 20, 497–499 (2017).

Article  PubMed  CAS  Google Scholar 

Arnold, C. Tailored treatment for ALS poised to move ahead. Nat. Med. https://doi.org/10.1038/d41591-019-00013-w (2019).

Article  PubMed  Google Scholar 

Cappella, M., Pradat, P.-F., Querin, G. & Biferi, M. G. Beyond the traditional clinical trials for amyotrophic lateral sclerosis and the future impact of gene therapy. J. Neuromuscul. Dis. 8, 25–38 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Korobeynikov, V. A., Lyashchenko, A. K., Blanco-Redondo, B., Jafar-Nejad, P. & Shneider, N. A. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat. Med. 28, 104–116 (2022).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mawr, B. Phase 3 trial of jacifusen for amyloid lateral sclerosis with fused-in-sarcoma mutation. Practical Neurology https://practicalneurology.com/news/phase-3-trial-of-jacifusen-for-amyloid-lateral-sclerosis-with-fused-in-sarcoma-mutation (2021).

Kim, J. et al. A framework for individualized splice-switching oligonucleotide therapy. Nature https://doi.org/10.1038/s41586-023-06277-0 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Merlot, J. Ataxia teleangiectatica: Wie Eltern eine experimentelle Therapie entdeckten [German]. Der Spiegel (2023); https://www.spiegel.de/wissenschaft/medizin/ataxia-teleangiectatica-wie-eltern-eine-experimentelle-therapie-entdeckten-a-f5c81ef8-0039-4a4e-960e-92c8ff8b5d0d.

Li, H. et al. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Sig Transduct. Target. Ther. 5, 1–23 (2020).

Article